Embed Size (px)
Citation preview
OVERVIEW OF THE NATIONAL INFLUENZA
VACCINE SUMMIT
OVERVIEW OF THE NATIONAL INFLUENZA
VACCINE SUMMITDennis J. O’Mara
Associate Director for Adult ImmunizationImmunization Services DivisionNational Immunization Program
Centers for Disease Control and PreventionDepartment of Health and Human Services
NVAC, Washington, D.C.June 3, 2003
2003
Summit conceived in response to delays in influenza vaccine production and distribution in 2000
Co-sponsored by AMA and CDC1st two Summits:
March and August 20013rd Summit in May 20024th Summit in May 2003
History of the National Influenza Vaccine Summit
History of the National Influenza Vaccine Summit
The Summit is . . .The Summit is . . .
An annual meetingA conceptAn informal, action-
oriented organizationA resource
Composition of the Summit (1)
Composition of the Summit (1)
Vaccine ManufacturersVaccine DistributorsFederal AgenciesProfessional Medical
OrganizationsPublic Health HospitalsPharmacists
Composition of the Summit (2)
Composition of the Summit (2)
Community Immunization ProvidersOccupational Health Providers BusinessPrivate Insurance and Managed
CareLong-term Care Quality Improvement OrganizationsConsumers
The 2003 Summit: Attendees
About 100 individuals attended54 organizations represented12/14 categories well-
represented2 categories (consumer groups
and business) need more representation
The 2003 Summit: Agenda
Plenary updatesFuture directions in vaccine
productionInfluenza pandemic planningBreakout sessions by working
group
Previously-ExistingSummit Working Groups
Previously-ExistingSummit Working Groups
CommunicationsCommunity-based Vaccination
ProvidersOccupational Vaccination
ProvidersPayment IssuesVaccine Distribution
NewSummit Working Groups
NewSummit Working Groups
Consumers’ IssuesVaccine ReallocationPhysicians’ IssuesLong-Term Care
Addressing the 50 Summit
Recommendations: Process
Addressing the 50 Summit
Recommendations: ProcessOne lead group/organization
per recommendationOther groups/organizations
in support as neededCollaboration as appropriatePeriodic updates on progress
collected and posted on AMA’s Summit website
Examples of Progress To Date
on 2002 RecommendationsMedicare vaccine administration
rates increased by an average of 94%
National Influenza Vaccination Catch-up Fortnight
Elimination of Medicare CPT Code for whole-cell influenza vaccine
Updated draft influenza vaccine storage and handling guidelines
Examples of Future Plans from Summit Working
Groups (1)Coordinated promotion/information
campaigns for providers and consumers
Coordinated campaign to promote extending the influenza vaccine campaign
List of provider vaccine ordering strategies
Examples of Future Plans from Summit Working
Groups (2)Vaccine reallocation model practices
databaseProvider organization messages to
members re: purchasing vaccine this year
Vaccine distribution system matrix
The Dual Challenge We FaceThe Dual Challenge We Face
To increase demand for and uptake of vaccine to approach true need
To increase vaccine supply to approximate the (growing?) demand
To increase demand for and uptake of vaccine to approach true need
To increase vaccine supply to approximate the (growing?) demand
Influenza VaccineRisk and Target Groups,
U.S., 2002
Influenza VaccineRisk and Target Groups,
U.S., 2002
GroupEstimated Population
(MILLIONS)
Increased risk* 83 (+2)
Target** 102
Others aged 2-49 years
101
All persons aged >5 mos.
286 * Includes children aged 6-23 months as of 7/1/02; 2 million children turn 6 months during
Oct.-March
** Includes health care personnel, household contacts of persons at increased risk (persons with medical indications, aged 65 or older, or aged <2 years), and other persons aged 50-64 years
PRELIMINARY ESTIMATES (1997-2001 National Health Interview Survey, 2000-2002 Census estimates)
Groups at Increased Riskfrom Influenza, U.S., 2002Groups at Increased Riskfrom Influenza, U.S., 2002
GroupEst.
Population(MILLIONS)
Aged >64 years 36Chronic illness Aged 50-64 years (30%) Aged 19-49 years (14%) Aged 6 mo.-18 years (11%)
39½ 13 18 8
Pregnant women 2Other children 6-23 months 5½Total at increased risk* 83 (+2)* Includes children aged 6-23 months as of 7/1/02; 2 million children turn 6 months during
Oct.-March
PRELIMINARY ESTIMATES (1997-2001 National Health Interview Survey, 2000-2002 Census estimates)
Influenza Vaccine Target Groups*, U.S.,
2002
Influenza Vaccine Target Groups*, U.S.,
2002Group
Est. Population
(MILLIONS)
Health care personnel <65 7
Household contacts** Aged 50-64 years (33%) Aged 19-49 years (35%) Aged 2-18 years (45%)
75½10 3828
Other persons aged 50-64 19½Total, other target groups 102
* Includes household members, but not out-of-home caretakers, of children aged <2 years
** Based on Monte Carlo imputation of increased risk status using 2000 NHIS; does not include household contacts of children born during influenza season
PRELIMINARY ESTIMATES (1997-2001 National Health Interview Survey, 2000-2002 Census estimates)
Influenza Vaccine DosesProduced for the U.S. Market,
1999-2002*
Influenza Vaccine DosesProduced for the U.S. Market,
1999-2002*
Year Number Doses Produced
1999 77.2 Million
2000 77.9 Million
2001 87.7 Million
2002 95.0 Million* Data provided by manufacturers producing
influenza vaccine for the U.S. market.
Increase VaccineDemand/UptakeIncrease VaccineDemand/Uptake
Increase Capacity of the Delivery System- Get more providers vaccinating- Get providers vaccinating more- Determine vaccination
opportunities based on community and provider norms
Community/Provider Influenza Vaccination
Norms
Community/Provider Influenza Vaccination
NormsWhat are the current
community coverage levels?Who vaccinates?Where/when do they vaccinate?What is the vaccination-
seeking behavior of the population?
and…
Community Influenza Vaccination Norms
Community Influenza Vaccination Norms
What is the general health care seeking behavior of the population?
What is the population’s perception of health care and providers?
What is the correct balance of vaccine delivery between:- Fixed health facilities- Non-traditional sites
Increase Vaccine SupplyIncrease Vaccine Supply
Maximize existing production capacity
Bring new manufacturers to the market
Employ new or improved vaccine production technology
A Vision of theFuture of the National
Influenza Vaccine Summit
A Vision of theFuture of the National
Influenza Vaccine SummitRemains a permanent but informal
organization at the national levelWorks year-round on the issuesFlexible — can respond to
contingenciesCould expand attention to broader
array of adult vaccination issues
Dennis J. O’MaraAssoc. Director Adult
Immunization
ISD / NIP / CDC1600 Clifton Road NE · MS E-52
Atlanta, GA 30333
Telephone: 404-639-8820Fax: 404-639-8615
E-mail: [email protected]
AMA Summit Web Site: http://www.ama-assn.org/ama/pub/article/1826-6268.html
